Aptose Biosciences Inc. (NASDAQ:APTO) Position Cut by Sigma Planning Corp

Sigma Planning Corp lowered its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 48.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 75,477 shares of the biotechnology company’s stock after selling 70,309 shares during the period. Sigma Planning Corp’s holdings in Aptose Biosciences were worth $192,000 as of its most recent filing with the SEC.

Separately, Annandale Capital LLC grew its position in Aptose Biosciences by 40.0% in the 3rd quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 21,334 shares during the last quarter. 26.62% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Trading Up 0.8 %

NASDAQ:APTO opened at $1.23 on Tuesday. The company has a 50-day moving average of $1.53 and a 200-day moving average of $2.09. Aptose Biosciences Inc. has a twelve month low of $1.15 and a twelve month high of $8.70. The firm has a market cap of $19.34 million, a price-to-earnings ratio of -0.16 and a beta of 1.29.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings results on Tuesday, March 26th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.48) by $0.04. On average, research analysts forecast that Aptose Biosciences Inc. will post -3.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

APTO has been the subject of several analyst reports. Piper Sandler reiterated an “overweight” rating and set a $5.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. StockNews.com upgraded shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, March 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Aptose Biosciences in a research report on Wednesday, March 27th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.80.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.